Ancestry (10)
- E1 - Principal component 1 (phv00375266.v1.p1)
- E10 - Principal component 10 (phv00375275.v1.p1)
- E2 - Principal component 2 (phv00375267.v1.p1)
- E3 - Principal component 3 (phv00375268.v1.p1)
- E4 - Principal component 4 (phv00375269.v1.p1)
- E5 - Principal component 5 (phv00375270.v1.p1)
- E6 - Principal component 6 (phv00375271.v1.p1)
- E7 - Principal component 7 (phv00375272.v1.p1)
- E8 - Principal component 8 (phv00375273.v1.p1)
- E9 - Principal component 9 (phv00375274.v1.p1)
Anthropometry (4)
- BMI - Body mass index (phv00375247.v1.p1)
- HEIGHT - Height (phv00375254.v1.p1)
- WEIGHT - Weight (phv00375261.v1.p1)
- WHratio - Waist/hip ratio (phv00375277.v1.p1)
Biomarkers (15)
- APOA1 - Apo A1 (phv00375245.v1.p1)
- APOB - Apo B (phv00375246.v1.p1)
- CHOL - Total cholesterol at baseline (phv00328560.v2.p1)
- CREA - Creatinine (phv00375248.v1.p1)
- CRP - CRP(Denka) (phv00375249.v1.p1)
- DBPCAT - Diastolic blood pressure (phv00375250.v1.p1)
- FIBRINOGEN - Fibrinogen (phv00375252.v1.p1)
- HBA1C - HbA1c (phv00375253.v1.p1)
- HCYS - Homocysteine (phv00375255.v1.p1)
- HDL - HDL cholesterol in mg/dl at baseline (phv00328558.v2.p1)
- ICAM - ICAM (phv00375256.v1.p1)
- LDL - LDL cholesterol in mg/dl at baseline, direct measure (phv00328557.v2.p1)
- LPA - Lp(a) (phv00375257.v1.p1)
- SBPCAT - Systolic blood pressure (phv00375259.v1.p1)
- TGGB - Triglycerides in mg/dl at baseline (phv00328559.v2.p1)
Demographics (4)
- age - Age at enrollment (phv00265848.v3.p1)
- age_diagnosis - Age at AF diagnosis (phv00265849.v3.p1)
- sex - Gender of participant (phv00265850.v3.p1)
- SEX - Sex/gender of subject (phv00530123.v1.p1)
Disease Events (2)
- diabetbs - Diabetes at baseline (phv00375262.v1.p1)
- uterinefibr - Uterine fibroids (phv00375265.v1.p1)
Exercise (1)
- EXERCISE - Exercise (phv00375258.v1.p1)
Medications (1)
- cholmeds1 - Cholesterol lowering medication at baseline (phv00328562.v2.p1)
Race and Ethnicity (1)
- race - Race of participant (phv00328556.v2.p1)
Reproductive Health (2)
- agemenarche - Age at menarche (phv00375264.v1.p1)
- agemeno - Age at menopause (phv00375276.v1.p1)
Study Administration (2)
- CONSENT - Consent group as determined by DAC (phv00258321.v3.p1)
- FAST8HRS - Baseline blood draw at least 8 hours after last meal (phv00328561.v2.p1)
Substance Use (2)
- ALCUSE - Alcohol use (phv00375251.v1.p1)
- SMK3CAT - Smoking status (phv00375260.v1.p1)
Other (17)
- af_status - AF status (phv00265847.v3.p1)
- ANALYTE_TYPE - Analyte Type (phv00258328.v2.p1)
- BODY_SITE - Body site where sample was collected (phv00258327.v2.p1)
- Funding_Source - Funding Source (phv00328564.v1.p1)
- IS_TUMOR - Tumor status (phv00258329.v2.p1)
- metabsyn - Metabolic syndrome (phv00375263.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00258326.v2.p1)
- SAMPLE_ID - Sample ID (phv00258324.v2.p1)
- SEQUENCING_CENTER - SEQUENCING CENTER (phv00328563.v1.p1)
- SOURCE_SUBJECT_ID - Subject ID from Source Study (phv00328555.v2.p1)
- Study_Name - Study Name (phv00328567.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00265846.v3.p1)
- SUBJECT_ID - Subject ID (phv00258320.v3.p1)
- SUBJECT_ID - Subject ID (phv00258323.v2.p1)
- SUBJECT_SOURCE - Source Study of Subject if other (phv00328554.v2.p1)
- TOPMed_Phase - TOPMed Phase (phv00328565.v1.p1)
- TOPMed_Project - TOPMed Project (phv00328566.v1.p1)